Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

@article{Eisen2000ContinuousLD,
  title={Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer},
  author={Tim G Eisen and Chris H. Boshoff and I Y H Mak and Francisco Sapunar and Margaret Mortensen Vaughan and Lynda M. Pyle and Stephen R. D. Johnston and Roger Ahern and Ian E. Smith and Martin Eric Gore},
  journal={British Journal of Cancer},
  year={2000},
  volume={82},
  pages={812 - 817}
}
To grow and metastasize, solid tumours must develop their own blood supply by neo-angiogenesis. Thalidomide inhibits the processing of mRNA encoding peptide molecules including tumour necrosis factor-alpha (TNF-α) and the angiogenic factor vascular endothelial growth factor (VEGF). This study investigated the use of continuous low dose Thalidomide in patients with a variety of advanced malignancies. Sixty-six patients (37 women and 29 men; median age, 48 years; range 33–62 years) with advanced… CONTINUE READING
85 Citations
34 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 85 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Thalidomide in Crohn’s disease

  • J N Engl
  • Wettstein AR and Meagher AP
  • 1997

Tumor angiogenesis metastasis – correlation in invasive breast cancer

  • AR Wettstein, AP Meagher
  • N Engl J Med
  • 1997

Experimental and clinical studies on the use o matrix metalloproteinase inhibitors for the treatment of cancer

  • JM Tramontana, U Utaipat, +6 authors G Kaplam
  • Eur J Cancer
  • 1996

Similar Papers

Loading similar papers…